Pulmonary delivery of 0.5 mg/kg/d MRI-1867 (zevaquenabant), a peripherally acting hybrid CB1R/iNOS inhibitor, was as effective as systemic delivery of 10 mg/kg/d and also matched the efficacy of nintedanib in mitigating bleomycin-induced PF. This evidence concerns the gene CNR1 and pemphigus foliaceus.